BRPI0413861A - compostos de pirimidotiofeno - Google Patents

compostos de pirimidotiofeno

Info

Publication number
BRPI0413861A
BRPI0413861A BRPI0413861-9A BRPI0413861A BRPI0413861A BR PI0413861 A BRPI0413861 A BR PI0413861A BR PI0413861 A BRPI0413861 A BR PI0413861A BR PI0413861 A BRPI0413861 A BR PI0413861A
Authority
BR
Brazil
Prior art keywords
alk
optionally substituted
hydrogen
compounds
alkyl
Prior art date
Application number
BRPI0413861-9A
Other languages
English (en)
Inventor
Brian William Dymock
Martin James Drysdale
Christophe Fromont
Allan Jordan
Original Assignee
Vernalis Cambridge Ltd
Cancer Rec Tech Ltd
Cancer Res Inst
Xavier Barril Alonso
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0320300A external-priority patent/GB0320300D0/en
Priority claimed from GB0327924A external-priority patent/GB0327924D0/en
Priority claimed from GB0414467A external-priority patent/GB0414467D0/en
Application filed by Vernalis Cambridge Ltd, Cancer Rec Tech Ltd, Cancer Res Inst, Xavier Barril Alonso filed Critical Vernalis Cambridge Ltd
Publication of BRPI0413861A publication Critical patent/BRPI0413861A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)

Abstract

"COMPOSTOS DE PIRIMIDOTIOFENO". A presente invenção refere-se aos compostos de fórmula (1) são inibidores da atividade de HSP90 in vitro ou in vivo e do uso no tratamento de, inter alia, do câncer: em que R~ 2~ é um grupo de fórmula -(Ar¬ 1¬)m-(ALk¬ 1¬)p-(Z)-(ALk¬ 2¬)s-Q em que Ar¬ 1¬ é um radical arila ou heteroarila opcionalmente substituído, Alk¬ 1¬ e Alk¬ 2¬ São radicais divalentes C~ 1~-C~ 3~ alquileno ou C~ 2~-C~ 3~ alquenileno opcionalmente substituídos, m, p, r e s são independentemente O ou 1, Z é -0-, -S-, -(C=O)-, -(C=S)-, -SO~ 2~-, -C(=0)0-, -C(=O)NR¬ A¬-, -C(=S)NR¬ A¬-, -SO~2~NR¬ A¬-, -NR¬ A¬C(=O)-, -NR¬ A¬S0~ 2~- ou -NR¬ A¬- em que R¬ A¬ é hidrogênio ou C~ 1~-C~ 6~ alquila e Q é hidrogênio ou um radical carbocíclico ou heterocíclico opcionalmente substituído; R~ 3~ é hidrogênio, um substituinte opcional ou um radical (C~ 1~,-C~ 6~) alquila, arila ou heteroarila opcionalmente substituido e R~ 4~ é um grupo éster carboxílico, carboxamida ou sulfonamida.
BRPI0413861-9A 2003-08-29 2004-08-26 compostos de pirimidotiofeno BRPI0413861A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0320300A GB0320300D0 (en) 2003-08-29 2003-08-29 Pyrimidothiophene compounds
GB0327924A GB0327924D0 (en) 2003-12-02 2003-12-02 Pyrimidothiophene compounds
GB0414467A GB0414467D0 (en) 2004-06-29 2004-06-29 Pyrimidothiophene compounds
PCT/GB2004/003641 WO2005021552A1 (en) 2003-08-29 2004-08-26 Pyrimidothiophene compounds

Publications (1)

Publication Number Publication Date
BRPI0413861A true BRPI0413861A (pt) 2006-10-24

Family

ID=34279360

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413861-9A BRPI0413861A (pt) 2003-08-29 2004-08-26 compostos de pirimidotiofeno

Country Status (12)

Country Link
US (2) US7820658B2 (pt)
EP (1) EP1675861B1 (pt)
JP (1) JP4783731B2 (pt)
KR (1) KR101139314B1 (pt)
AU (1) AU2004268820B2 (pt)
BR (1) BRPI0413861A (pt)
CA (1) CA2537135C (pt)
EA (1) EA009920B1 (pt)
ES (1) ES2559779T3 (pt)
NO (1) NO20061416L (pt)
NZ (1) NZ546044A (pt)
WO (1) WO2005021552A1 (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0416168D0 (en) * 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
BRPI0519243A2 (pt) * 2004-12-22 2009-01-06 Neurochem Int Ltd mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
AU2006230447A1 (en) * 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
DE102005022977A1 (de) * 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
DE102005024245A1 (de) * 2005-05-27 2006-11-30 Merck Patent Gmbh Thienopyridine
RU2441010C2 (ru) * 2005-12-21 2012-01-27 Эбботт Лэборетриз Противовирусные соединения
AU2007207536A1 (en) * 2006-01-17 2007-07-26 Signal Pharmaceuticals, Llc Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith
EA200801968A1 (ru) * 2006-03-11 2009-02-27 Вернэлис (Р&Д) Лтд. Пирролопиримидиновые производные, используемые в качестве ингибиторов hsp90
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
WO2007131034A1 (en) * 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
WO2008059368A2 (en) * 2006-11-17 2008-05-22 Pfizer Products Inc. Fused 2-amino pyrimidine compounds and their use for the treatment of cancer
AU2008211729A1 (en) 2007-02-01 2008-08-07 Astrazeneca Ab 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors
MX2009008756A (es) 2007-03-01 2009-08-27 Chugai Pharmaceutical Co Ltd Compuesto macrociclico.
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
DE102007028521A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
PL2200985T3 (pl) 2007-09-14 2011-12-30 Ortho Mcneil Janssen Pharmaceuticals Inc 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
CN101801930B (zh) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
GB0718433D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
NZ713361A (en) * 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
EA201490230A1 (ru) 2011-07-08 2014-06-30 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Применение меченых ингибиторов hsp90
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
JP6478908B2 (ja) 2012-05-25 2019-03-06 バーグ エルエルシー 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法
GB201217704D0 (en) * 2012-10-03 2012-11-14 Ucb Pharma Sa Therapeutic agents
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
US20150031697A1 (en) * 2013-07-26 2015-01-29 Wisconsin Alumni Research Foundation Method for preventing ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomas
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
EP3116867A4 (en) * 2014-03-11 2017-10-18 Godavari Biorefineries Ltd. Cancer stem cell targeting compounds
AU2015228385A1 (en) * 2014-03-11 2016-09-15 Godavari Biorefineries Limited Compounds for eradicating or inhibiting proliferation of cancer stem cells
JP6607870B2 (ja) 2014-05-13 2019-11-20 メモリアル スローン ケタリング キャンサー センター Ｈｓｐ７０モジュレーターならびにその作製および使用方法
WO2015188198A2 (en) 2014-06-06 2015-12-10 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
JP6779867B2 (ja) * 2014-06-13 2020-11-04 ユマ セラピューティクス，インコーポレーテッド ピリミジン化合物およびその使用方法
CN107921025A (zh) * 2015-03-08 2018-04-17 卡斯西部储备大学 用于治疗纤维症的短链脱氢酶活性的抑制剂
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
WO2018187810A1 (en) 2017-04-07 2018-10-11 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
FI3904350T3 (fi) * 2018-04-12 2023-11-15 Bayer Ag N-(syklopropyylimetyyli)-5-(metyylisulfonyyli)-n-{1-[1-(pyrimidin-2-yyli)-1h-1,2,4-triatsol-5-yyli]etyyli}bentsamidijohdannaisia ja vastaavia pyridiinikarboksamidijohdannaisia tuholaistorjunta-aineina
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
CN115124550B (zh) * 2020-10-26 2024-04-02 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用
WO2022089449A1 (zh) * 2020-10-26 2022-05-05 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0438261A3 (en) * 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
JPH0578362A (ja) * 1990-01-16 1993-03-30 Takeda Chem Ind Ltd 縮合複素環化合物，その製造法，用途及び中間体
WO2003037860A2 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine

Also Published As

Publication number Publication date
KR101139314B1 (ko) 2012-04-26
EA009920B1 (ru) 2008-04-28
JP2007533611A (ja) 2007-11-22
CA2537135A1 (en) 2005-03-10
NZ546044A (en) 2009-09-25
AU2004268820B2 (en) 2011-07-21
EA200600509A1 (ru) 2006-08-25
US20100120767A1 (en) 2010-05-13
EP1675861B1 (en) 2015-12-23
NO20061416L (no) 2006-05-23
CA2537135C (en) 2013-10-08
ES2559779T3 (es) 2016-02-15
EP1675861A1 (en) 2006-07-05
JP4783731B2 (ja) 2011-09-28
KR20070055414A (ko) 2007-05-30
US8642594B2 (en) 2014-02-04
US20070043044A1 (en) 2007-02-22
HK1095591A1 (en) 2007-05-11
US7820658B2 (en) 2010-10-26
AU2004268820A1 (en) 2005-03-10
WO2005021552A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
BRPI0413861A (pt) compostos de pirimidotiofeno
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
BRPI0407403A (pt) compostos de isoxanol
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
EA200600973A1 (ru) ПИРИДО[2,3-d] ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2
DE602004007239D1 (de) 4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN
DK1678166T3 (da) Proteinkinaseinhibitorer
BR9806413A (pt) Composto e uso do mesmo
SG151260A1 (en) 5-substituted-2-phenylamino-benzamides as mek inhibitors
BR0307517A (pt) Tripeptìdeos heterocìclicos como inibidores de hepatite c
NO20024154L (no) Pyrimidinforbindelser
BRPI0514632A (pt) derivados de ftalazinona 4-heteroarilmetila substituìdos
ATE406365T1 (de) Substituierte indazolyl(indolyl)maleimid-derivate als kinase inhibitoren
TW200732336A (en) Alyphactic heterocyclic compounds
UY28149A1 (es) Compuestos quimicos
DE60111205D1 (de) Triarylimidazol-derivate als cytokin-inhibitoren
UA99485C2 (ru) Хиназолиндионовые производные, их получение и их применение в терапии
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
IL198267A0 (en) Ikk-?? serine-threonine protein kinase inhibitors
TW200531683A (en) Aryl- and heteroarylpiperidinecarboxylate derivatives, their preparation and their application in therapeutics
EA201000017A1 (ru) Предварительная композиция серного цемента и способ приготовления предварительной композиции серного цемента
BRPI0508464B8 (pt) sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos
DE60219911D1 (de) Pyrrolidin-2-on derivate als faktor xa inhibitoren
WO2003082861A3 (en) Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
BRPI0508072A (pt) derivados de piperidinilalquicarbamatos, o respectivo preparo e a respectiva aplicação como inibidores da enzima faah

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: CANCER RESEARCH TECHNOLOGY LTD. (GB) , THE INSTITU

B25A Requested transfer of rights approved

Owner name: CANCER RESEARCH TECHNOLOGY LTD. (GB) , THE INSTITU

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time